MOLOGEN AG
MOLOGEN AG: Recruitment for the TEACH study with MGN1703 in HIV-patients completed (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Study PRESS RELEASE N 15 / 2015 of 09/22/2015 MOLOGEN AG: Recruitment for the TEACH study with MGN1703 in HIV-patients completed Berlin, September 22, 2015 – The biotechnology company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, completed enrollment of 16 HIV patients for the phase I TEACH study with the immunotherapy MGN1703. Results are expected in the second quarter of 2016. The aim of the TEACH study is to see if the immunotherapy with MGN1703 can activate the innate and adaptive immune system in HIV (Human Immunodeficiency Virus) patients to enhance killing of the HIV infected cells. Aarhus University Hospital is conducting the trial in two hospital centers in Denmark and already received respective funding from the American Foundation for AIDS Research (amfAR). MOLOGEN is providing the immunomodulator MGN1703. This is the first time that MGN1703 is evaluated in patients with diseases other than cancer. Thus the potential range of applications of the product could be expanded. “We are pleased that the enrollment for TEACH has been completed and that treatment with MGN1703 is well tolerated. We look forward to seeing all the results next year”, said Dr. Alfredo Zurlo, Chief Medical Officer of MOLOGEN AG. Furthermore, MGN1703 is currently being investigated in the registration trial IMPALA in colorectal cancer and in the randomized trial IMPULSE in small cell lung cancer. Both studies are currently enrolling patients. About TEACH The primary endpoint of the study is the change in proportions of activated natural killer cells in the patients. Secondary study endpoints include, among others, a collection of safety, virological, immunological and pharmacodynamic data. HIV infects the immune system and destroys or affects the proper function of immune cells. Without antiretroviral treatment this eventually leads to immune deficiency and the immune system can no longer fight off a wide range of infections and diseases. HIV remains a serious worldwide health issue. According to estimates by WHO and UNAIDS (United Nations Programme on AIDS) 35 million people worldwide were living with HIV at the end of 2013. Some 2.1 million people became newly infected in that same year, and 1.5 million died as a result of HIV-related causes globally. MGN1703 MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=NHFVARYANC Document title: MOLOGEN AG: Recruitment for the TEACH study with MGN1703 in HIV-patients completed 2015-09-22 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |
396511 2015-09-22 |